Alterity Therapeutics Limited
Alterity Therapeutics Limited
Your view on ATH.AX
Overview
What the company does, where it operates, and who runs it.
About Alterity Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David A. Stamler
- Headquarters
- 500 Collins Street, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David A. Stamler
- Headquarters
- 500 Collins Street, Melbourne, VIC, AU
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others.
The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials.
The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Alterity Therapeutics Limited. Starting points for Alterity Therapeutics Limited: EPS -AUD 0.11, beta -0.04 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Alterity Therapeutics Limited. Alterity Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Alterity Therapeutics Limited. Trailing twelve-month EPS for Alterity Therapeutics Limited stands at -AUD 0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Analyst ratings
2 ratings- Strong Buy0
- Buy2
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | −AUD 0.00 | −AUD 0.01 | −AUD 0.01 | −AUD 0.02 |
| Lowest estimate | −AUD 0.00 | −AUD 0.01 | −AUD 0.01 | −AUD 0.02 |
| Highest estimate | −AUD 0.00 | −AUD 0.01 | −AUD 0.01 | −AUD 0.02 |
| Number of analysts | 1 | 1 | 4 | 5 |
| A year ago | −AUD 0.10 | −AUD 0.04 | −AUD 0.111 | — |
| Growth vs a year ago | +96.9% | +80.3% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 1.13M | AUD 1.43M | AUD 2.34M | AUD 4.87M |
| Lowest estimate | AUD 1.13M | AUD 1.43M | AUD 2.34M | AUD 4.87M |
| Highest estimate | AUD 1.13M | AUD 1.43M | AUD 2.34M | AUD 4.87M |
| Number of analysts | 1 | 1 | 6 | 6 |
| A year ago | AUD 1.61M | AUD 3.83M | AUD 0.00 | — |
| Growth vs a year ago | −29.4% | −62.6% | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Alterity Therapeutics Limited. Alterity Therapeutics Limited has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACW.AXActinogen Medical Limited | Healthcare | Biotechnology | — | ||
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| ALA.AXArovella Therapeutics Limited | Healthcare | Biotechnology | — | ||
| IXC.AXInvex Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| NEU.AXNeuren Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| NSB.AXNeuroScientific Biopharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| NUZ.AXNeurizon Therapeutics Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| OZYMFStrategic Partners A/S | Healthcare | OTC | $3.7M | ||
| PAB.AXPatrys Limited | Healthcare | ASX | — | ||
| PALIPalisade Bio, Inc. | Healthcare | NASDAQ | $168.9M | ||
| PANCPanacos Pharmaceuticals, Inc. | Healthcare | OTC | $5,367 | ||
| PAR.AXParadigm Biopharmaceuticals Limited | Healthcare | ASX | — | ||
| PARDPoniard Pharmaceuticals, Inc. | Healthcare | OTC | $150 | ||
| PASGPassage Bio, Inc. | Healthcare | NASDAQ | $12.9M | ||
| PBIGFParadigm Biopharmaceuticals Limited | Healthcare | OTC | $87.9M | ||
| PBLAPanbela Therapeutics, Inc. | Healthcare | OTC | $53,889 | ||
| PBLSParabilis Medicines, Inc. | Healthcare | NASDAQ | $3.5B | ||
| PBMPsyence Biomedical Ltd. | Healthcare | NASDAQ | $47,738 | ||
| PBMWWPsyence Biomedical Ltd. Warrant | Healthcare | NASDAQ | $869 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Alterity Therapeutics Limited. Coverage tracks Alterity Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Alterity Therapeutics Limited.